AlphAIAlphAI — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$CING

Cingulate Inc.

Price · $CINGvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $CING in the last 7 days.

Insider · 30dAll trades →

No SEC Form 4 filings for $CING in the last 30 days.

See all $CING insider activity →
Top stories · $CINGMore →
OCT 2·SEC EDGAR 8-KLow

Cingulate Inc. (CING): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cingulate Inc. (CING) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 30, 2026, Cingulate Therapeutics LLC (“CTx”), a wholly owned subsidiary of Cingulate Inc. (the “Company”), ent

AUG 15·stocktwits.com

Why Is CING Stock Jumping Over 4% In Overnight Trading?

Cingulate Inc. (CING) shares rose more than 4% in overnight trading after the USPTO allowed a patent application for a “Trimodal, Precision-Timed Pulsatile Release Tablet” tied to its ADHD drug platform. CING said the allowed status follows a filing in Nov 2023 and comes ahead of an FDA decision on CTx-1301, with a May 31 PDUFA target date.

AUG 13·tradingview.com

Cingulate Inc. Q2 2026: Revenue $0 Net loss $5.87M — 10-Q Summary

Cingulate Inc. (CING) filed its Q2 2026 10-Q. It reported $0 product revenue and a net loss of $5.87M for the three months ended June 30, 2026, versus a $4.98M net loss in the prior-year quarter. The company said it received an FDA complete response letter for CTx-1301 requesting additional CMC data and outlined CMC and launch preparation plans.

CING sentiment & insider activity

Recent CING coverage spans corporate actions, regulation and market movers.

What's driving CING

  • The amendment is a routine corporate governance update with no material financial impact.

    SEC EDGAR 8-K · Oct 2, 2026

  • USPTO allowance adds IP validation for CTx-1301 delivery technology ahead of the FDA PDUFA decision window.

    stocktwits.com · Aug 15, 2026

  • FDA CMC-focused CRL increases regulatory timeline risk for CTx-1301, while cash runway and manufacturing/CMC work aim to mitigate delays.

    tradingview.com · Aug 13, 2026

  • The filing is a near-term catalyst for CTx-1301 regulatory timing and runway, with additional commercialization contracts that can de-risk launch execution if approval follows.

    SEC EDGAR 8-K · Aug 13, 2026

  • Board action removes a C-suite legal function and signals a potential shift in governance, compliance, or legal resourcing.

    SEC EDGAR 8-K · Jul 23, 2026

AlphAI scores every news story that mentions CING with an AI model for sentiment and relevance, and aggregates insider trades from Cingulate Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CING

Score
OCT 2$CINGLowSEC EDGAR 8-K

Cingulate Inc. (CING): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cingulate Inc. (CING) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 30, 2026, Cingulate Therapeutics LLC (“CTx”), a wholly owned subsidiary of Cingulate Inc. (the “Company”), ent

1 min read
AUG 15$CINGMedstocktwits.com

Why Is CING Stock Jumping Over 4% In Overnight Trading?

Cingulate Inc. (CING) shares rose more than 4% in overnight trading after the USPTO allowed a patent application for a “Trimodal, Precision-Timed Pulsatile Release Tablet” tied to its ADHD drug platform. CING said the allowed status follows a filing in Nov 2023 and comes ahead of an FDA decision on CTx-1301, with a May 31 PDUFA target date.

4 min read
AUG 13$CINGMedtradingview.com

Cingulate Inc. Q2 2026: Revenue $0 Net loss $5.87M — 10-Q Summary

Cingulate Inc. (CING) filed its Q2 2026 10-Q. It reported $0 product revenue and a net loss of $5.87M for the three months ended June 30, 2026, versus a $4.98M net loss in the prior-year quarter. The company said it received an FDA complete response letter for CTx-1301 requesting additional CMC data and outlined CMC and launch preparation plans.

1 min read
AUG 13$CINGMedSEC EDGAR 8-K

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Cingulate Inc. (CING) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness Cash and Cash Equivalents of $28.4 Million as of June 30, 2026 Providing Runway Through Mid-2027; Company Advan

6 min read
JUL 23$CINGLowSEC EDGAR 8-K

Cingulate Inc. (CING): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cingulate Inc. (CING) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001862150 0001862150 2026-07-17 2026-07-17 0001862150 CING:CommonStockParValue0.0001PerShareMember 2026-07-17 2026-07-17 0001862150 CING:WarrantsExercisableForCommonStockMember 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES

2 min read
JUL 14$CINGLowSEC EDGAR 8-K

Cingulate Inc. (CING): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cingulate Inc. (CING) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001862150 0001862150 2026-07-09 2026-07-09 0001862150 CING:CommonStockParValue0.0001PerShareMember 2026-07-09 2026-07-09 0001862150 CING:WarrantsExercisableForCommonStockMember 2026-07-09 2026-07-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES

4 min read
JUL 2$CINGLowSEC EDGAR 8-K

Cingulate Inc. (CING): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cingulate Inc. (CING) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001862150 0001862150 2026-06-30 2026-06-30 0001862150 CING:CommonStockParValue0.0001PerShareMember 2026-06-30 2026-06-30 0001862150 CING:WarrantsExercisableForCommonStockMember 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES

4 min read
JUN 3$BJDXMedAI 9/10finanzen.ch

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin

6 min read
JUN 3$BJDXMedAI 9/10rttnews.com

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare biotech gainers on Tuesday included Bluejay Diagnostics (BJDX), which said it signed a strategic partnership with Argonaut to support its Symphony near-patient diagnostic platform; BJDX shares rose 100% to $4.34 and the company also announced a private placement up to $23.6M. Picard Medical (PMI) reported completed animal implant studies for its next-gen Emperor total artificial heart; shares rose 60.33% to $0.27. Legend Biotech (LEGN) said it will present Phase 1 data for LB2501 show

5 min read

Related tickers

More in Biotechnology